Considering that human tumor-infiltrating NK cells display a similar CD56brightCD16neg TGF-β imprinted phenotype, NK cell-based therapies might benefit from using TGF-β receptor deficient CD56brightCD16neg NK cells. Here, TGFB1 is linked to neoplasm.